Suraksha Diagnostic Ltd

AI
Suraksha Diagno. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Suraksha Diagnostic Ltd

₹ 356 1.73%
11 Nov - close price
surakshanet.com BSE: 544293 NSE: SURAKSHA
About

Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]

Key Points

Business Model:[1][2][3]
a) Integrated Services:
Offers a one-stop solution for pathology, radiology, and medical consultancy services.
b) Comprehensive Testing:
Provides 1,000+ pathology tests and 450+ radiology tests.
c) Hub and Spoke Model:
Operates through 1 Central Reference Lab, 7 Satellite Labs (co-located with hub centres), 16 Hub Centres, and 46 Spoke Centres (34 Small, 12 Medium, 6 PPP), with 193 Collection Centres and 4 Company Owned Collection Centres.
d) Omni-channel Consultation:
Combines online and offline medical consultation services, leveraging its polyclinics with 1,000+ doctors.
e) B2C-Focused Revenue Model:
Primarily serves individual patients,
with some revenue from B2B contracts.

Website BSE NSE
  • Market Cap ₹ 1,856 Cr.
  • Current Price ₹ 356
  • High / Low ₹ 384 / 224
  • Stock P/E 43.4
  • Book Value ₹ 53.3
  • Dividend Yield 0.14 %
  • ROCE 17.8 %
  • ROE 14.8 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has delivered good profit growth of 33.2% CAGR over last 5 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
60 51 55 60 66 59 64 70 76 76 79 84 95
39 36 35 39 42 40 44 46 52 52 55 55 61
Operating Profit 21 16 20 21 24 18 20 24 24 23 24 29 34
OPM % 35% 30% 36% 35% 36% 31% 31% 34% 31% 31% 30% 34% 36%
1 1 0 1 1 1 1 1 1 1 1 2 2
Interest 2 2 2 2 2 2 2 3 3 3 4 4 5
Depreciation 8 8 8 9 9 9 9 9 10 10 11 11 12
Profit before tax 11 7 10 11 14 8 10 13 13 11 11 16 19
Tax % 24% 24% 30% 26% 24% 24% 20% 25% 25% 26% 36% 22% 20%
9 5 7 8 11 6 8 10 9 8 7 13 15
EPS in Rs 2.01 1.14 1.59 1.93 2.49 1.22 1.54 1.89 1.80 1.56 1.29 2.42 2.94
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
132 151 158 140 223 190 219 249 301 333
105 115 123 115 175 142 144 166 205 223
Operating Profit 27 36 34 25 48 48 74 84 96 110
OPM % 20% 24% 22% 18% 22% 25% 34% 34% 32% 33%
1 1 2 -1 2 1 1 4 4 6
Interest 4 2 2 2 2 10 10 9 13 15
Depreciation 12 12 13 16 15 32 33 35 40 43
Profit before tax 12 23 21 6 33 8 33 44 47 57
Tax % 28% 17% 28% -1% 28% 9% 25% 24% 28%
9 19 15 6 24 7 24 33 34 43
EPS in Rs 2.08 4.42 3.53 1.50 5.51 1.67 5.66 6.42 6.54 8.21
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 1%
Compounded Sales Growth
10 Years: %
5 Years: 17%
3 Years: 17%
TTM: 24%
Compounded Profit Growth
10 Years: %
5 Years: 33%
3 Years: 59%
TTM: 27%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 14%
Return on Equity
10 Years: %
5 Years: 14%
3 Years: 16%
Last Year: 15%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 7 7 7 7 7 7 7 10 10 10
Reserves 79 96 111 118 141 148 172 204 239 267
27 22 13 18 21 99 92 89 128 153
33 43 42 28 32 29 30 30 72 87
Total Liabilities 145 168 173 171 201 282 302 333 450 518
96 127 128 119 119 195 211 215 284 350
CWIP 6 0 0 0 1 2 1 6 37 17
Investments 10 2 5 6 0 0 1 3 6 7
33 38 39 46 80 84 88 109 123 145
Total Assets 145 168 173 171 201 282 302 333 450 518

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
31 24 42 45 61 63 80
-20 -28 -44 -22 -35 -39 -51
-10 3 1 -24 -26 -24 -28
Net Cash Flow 1 -1 -0 -1 0 -1 1
Free Cash Flow 15 5 24 32 22 28 30
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 111% 100% 97% 109% 94% 88% 97%

Ratios

Standalone / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 14 16 14 16 12 9 15 22 30
Inventory Days 90 107 93 62 38 81 89 101 82
Days Payable 256 176 227 177 84 184 192 176 196
Cash Conversion Cycle -151 -54 -120 -99 -34 -95 -88 -53 -84
Working Capital Days -9 6 -35 -19 -15 -48 -36 -14 -23
ROCE % 21% 18% 8% 23% 9% 17% 18% 18%

Insights

In beta
Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Number of Collection Centres
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Diagnostic Centres
Number
Number of Doctors (Radiologist & Pathologist)
Number
Number of Imaging Machines (MRI + CT)
Number
Number of Laboratories
Number
Number of Patients Served
Million patients
Number of Tests per Patient
Tests per patient
Number of Tests Performed
Million tests

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
48.78% 48.78% 48.89% 48.98% 49.00% 49.10% 49.10% 49.10%
15.39% 14.46% 13.95% 13.73% 13.46% 13.46% 13.47% 13.98%
20.43% 22.05% 22.37% 21.98% 22.57% 23.14% 23.22% 21.56%
15.39% 14.71% 14.79% 15.30% 14.98% 14.31% 14.20% 15.37%
No. of Shareholders 98,66287,27579,67075,30470,96367,10764,86660,792

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls